Skip to content
BeOne Medicines
-
BeOne Medicines secures US$20M option on Huahui Health’s trispecific cancer antibody HH160
If fully developed and commercialized, Huahui Health could receive up to US$1.9 billion in milestone-based payments, in addition to tiered royalties on future global sales.